Management of Decompensated Cirrhosis with Portal Hypertension and Ascites

Immediate Etiological Treatment

The American Association for the Study of Liver Diseases recommends treating the underlying cause of cirrhosis, which is the single most important intervention that reduces mortality and prevents further decompensation, with alcohol cessation and antiviral therapy for hepatitis B/C 1, 3
The European Association for the Study of the Liver suggests that complete and permanent cessation of alcohol is mandatory for patients with alcohol-related cirrhosis and may lead to "re-compensation" with improved outcomes 3, 4
The American Association for the Study of Liver Diseases recommends initiating entecavir (1 mg daily for decompensated patients) or tenofovir monotherapy regardless of HBV DNA level for patients with hepatitis B 3, 4
The European Association for the Study of the Liver suggests that direct-acting antivirals improve liver function and reduce portal hypertension in patients with hepatitis C 4
The American Association for the Study of Liver Diseases recommends immunosuppressive therapy for patients with autoimmune hepatitis, which shows beneficial effects even in decompensated cirrhosis 4

The European Association for the Study of the Liver recommends performing diagnostic paracentesis immediately in all patients with new onset grade 2-3 ascites or any hospitalization for cirrhosis complications, and inoculating at least 10 ml of ascitic fluid into blood culture bottles at bedside to enhance culture sensitivity 1, 5
The American Association for the Study of Liver Diseases suggests measuring neutrophil count (>250 cells/µl indicates spontaneous bacterial peritonitis requiring immediate antibiotics) and assessing total protein concentration (<1.5 g/dl indicates higher SBP risk) 1, 5
The European Association for the Study of the Liver recommends calculating serum-ascites albumin gradient (SAAG) if cirrhosis diagnosis is uncertain 5

The American Association for the Study of Liver Diseases recommends sodium restriction to 90 mmol/day (5.2 g salt/day) for patients with grade 1 ascites (mild, detected only by ultrasound) 2, 4
The European Association for the Study of the Liver suggests initiating spironolactone 50-100 mg daily, titrating up to maximum 400 mg daily, for patients with grade 2 ascites (moderate, detectable on physical exam) 2, 4
The American Association for the Study of Liver Diseases recommends adding furosemide 20-40 mg daily (maximum 160 mg daily) if inadequate response to spironolactone alone, and targeting weight loss of 0.5 kg/day in patients without peripheral edema, or 1 kg/day in those with edema 2, 4

The European Association for the Study of the Liver recommends antibiotic prophylaxis with norfloxacin 400 mg orally twice daily for patients with ascitic protein <1.5 g/dl or prior SBP, and ceftriaxone 1 g IV every 24 hours for up to 7 days in decompensated cirrhosis with GI bleeding or quinolone-resistant settings 2, 3

The American Association for the Study of Liver Diseases recommends performing esophagogastroduodenoscopy (EGD) to screen for varices in all newly decompensated patients, and using non-selective beta-blockers (propranolol or carvedilol) to prevent first variceal bleeding and reduce risk of ascites, hepatorenal syndrome, and SBP beyond variceal prevention alone 3, 7
The European Association for the Study of the Liver suggests that endoscopic band ligation is equally effective as beta-blockers for primary prophylaxis of high-risk varices 7

The American Association for the Study of Liver Diseases defines ascites recurring at least three times within 12 months despite adequate sodium restriction and maximum diuretic doses (spironolactone 400 mg + furosemide 160 mg daily) as refractory, and recommends serial large-volume paracentesis with albumin replacement (8 g/L removed) every 2-4 weeks 1, 2, 4
The European Association for the Study of the Liver suggests that transjugular intrahepatic portosystemic shunt (TIPS) in highly selected patients reduces further decompensation and improves survival, and that immediate liver transplant evaluation is necessary for patients with refractory ascites 2, 4

The American Association for the Study of Liver Diseases states that five-year survival drops from 80% in compensated cirrhosis to 30% with decompensated cirrhosis and ascites, underscoring the urgency of early transplant evaluation 1, 6
The European Association for the Study of the Liver recommends considering palliative care referral for non-transplant candidates with refractory ascites 4